Shelter Pharma Limited has secured a significant international order worth $18,300 from First Vet Veterinary Medicines Trading LLC, UAE, for the supply of veterinary and animal healthcare products. The company announced this development on March 12, 2024, in compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

Order Details and Specifications

The contract represents a fixed-cost arrangement with the UAE-based veterinary medicines trading company, with execution scheduled within 6 months. The order focuses on veterinary and animal healthcare products, expanding Shelter Pharma's international footprint in the animal health segment.

Regulatory Compliance and Corporate Governance

Shelter Pharma Limited has confirmed that this transaction maintains high standards of corporate governance. The company disclosed that promoters and promoter group companies have no interest in the entity that awarded the order. Additionally, the contract does not fall within related party transactions, ensuring arm's length dealing principles.

About Shelter Pharma Limited

Shelter Pharma Limited operates as a leading pharmaceutical and nutraceutical company with a strong focus on research, innovation, and quality. The company maintains state-of-the-art facilities and employs a world-class team of experts committed to ethical practices. Founded with a vision to provide accessible and effective healthcare solutions, Shelter Pharma has established itself as a trusted name in the industry by consistently delivering products that adhere to the highest industry standards.

The company's mission centers on promoting well-being and health through innovative, high-quality nutraceuticals. Shelter Pharma takes pride in its recognition for producing safe and effective products that enhance quality of life for individuals globally, guided by strong ethical codes and deep social responsibility.

Shelter Pharma Limited has successfully completed the conversion of 2,79,000 warrants into equity shares, raising ₹88.40 lakh through the exercise of conversion rights by non-promoter warrant holders. The board of directors approved this conversion during their meeting held on March 07, 2026, as disclosed in the official regulatory filing to BSE Limited.

Board Meeting Outcome and Regulatory Compliance

The conversion was executed in accordance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The board meeting commenced at 12:15 PM and concluded at 12:45 PM, with the directors approving the allotment of 2,79,000 equity shares of face value ₹10.00 each upon warrant conversion.

Investor Participation Details

Three non-promoter investors participated in the warrant conversion process with varying levels of participation. Rishabh Nayambhai Sharma converted 99,000 warrants out of his total holding of 5,40,000, having previously converted 2,01,000 warrants. Nayana Kamlesh Sheth fully converted her entire holding of 1,02,000 warrants, while Dipika Pankajbhai Patel converted 78,000 out of her 99,000 warrants.

Capital Structure Enhancement

The warrant conversion has resulted in a substantial increase in the company's paid-up equity share capital. The capital base expanded from ₹16.33 crore consisting of 1.63 crore equity shares to ₹16.61 crore comprising 1.66 crore equity shares, each with a face value of ₹10.00.

Background and Future Steps

The original warrant allotment of 88.08 lakh warrants was approved by shareholders at an extraordinary general meeting held on July 23, 2025, with BSE providing in-principle approval on July 22, 2025. The warrants were issued at ₹42.25 each with warrant holders paying 25% upfront and the remaining 75% upon conversion.

The newly allotted equity shares will rank pari-passu with existing equity shares in all respects, ensuring equal rights for all shareholders. The company will submit applications for listing and trading approval of the newly issued equity shares to the stock exchange in due course. The successful conversion demonstrates continued investor confidence in the company's growth prospects and provides additional capital for business operations.